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RESEARCH ARTICLE
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ABSTRACT
Cell migration is a complex process requiring density and rigidity
sensing of the microenvironment to adapt cell migratory speed through
focal adhesion and actin cytoskeleton regulation. ICAP-1 (also known
as ITGB1BP1), a β1 integrin partner, is essential for ensuring integrin
activation cycle and focal adhesion formation. We show that ICAP-1 is
monoubiquitylated bySmurf1, preventing ICAP-1binding to β1 integrin.
The non-ubiquitylatable form of ICAP-1 modifies β1 integrin focal
adhesion organization and interferes with fibronectin density sensing.
ICAP-1 is also required for adapting cell migration in response to
substrate stiffness in a β1-integrin-independent manner. ICAP-1
monoubiquitylation regulates rigidity sensing by increasing MRCKα
(also known as CDC42BPA)-dependent cell contractility through
myosin phosphorylation independently of substrate rigidity. We
provide evidence that ICAP-1 monoubiquitylation helps in switching
from ROCK2-mediated to MRCKα-mediated cell contractility. ICAP-1
monoubiquitylation serves as a molecular switch to coordinate
extracellular matrix density and rigidity sensing thus acting as a
crucial modulator of cell migration and mechanosensing.
KEY WORDS: Cell migration, Rigidity sensing, ICAP-1, Integrin,
Monoubiquitylation, Cell contractility
INTRODUCTION
Motile cells continuously sample in space and time the
heterogeneity in the composition and stiffness of their
extracellular matrix (ECM) through integrin-mediated focal
adhesions (FAs) (Moore et al., 2010). As a mechanical link
between ECM and actin stress fibers, integrins are crucial for force
transmission and signal transduction (Moore et al., 2010). FA
assembly, growth and maintenance depend on actomyosin traction
forces, which adapt to the substrate elasticity (Burridge and
Wittchen, 2013). In spite of alternative pathways involving
MRCK (which has two isoforms, MRCKα and MRCKβ, also
known as CDC42BPA and CDC42BPB, respectively), MLCK (also
known as MYLK) or mDia (Burridge and Wittchen, 2013; Chen
et al., 2014; Jégou et al., 2013; Totsukawa et al., 2004), a key event
is the modulation of cellular contractility through myosin-based
contractility and ROCK (which has two isoforms, ROCK1 and
ROCK2) activity. However, signaling pathways underlying
FA-mediated rigidity sensing and the mechano-response are not
fully understood.
ICAP-1 (also known as ITGB1BP1), a negative regulator of β1
integrin, enables the cell to sense ECM density to adapt its adhesive
and migratory responses (Millon-Frémillon et al., 2008) and to
control fibronectin (FN) remodeling (Brunner et al., 2011; Faurobert
et al., 2013). ICAP-1 specifically binds to the cytoplasmic tail of β1
integrin, maintaining the integrin in its inactivated form by competing
with the two activators named Kindlin and talin (Brunner et al., 2011;
Millon-Frémillon et al., 2008; Montanez et al., 2008; Ye et al., 2014).
ICAP-1 also binds to ROCK1 (Peter et al., 2006). Thanks to these
interactions, ICAP-1 may be a good candidate for regulating myosin-
based contractility and cellular response to ECM stiffness. Tunable
post-translational modifications may control ICAP-1 functions
enabling the cell to adapt its migratory response. As ubiquitylation
is emerging as important for cell migration dynamics and cell
contractility (Carvallo et al., 2010; Sahai et al., 2007; Schaefer et al.,
2012; Su et al., 2013; Wang et al., 2003), we addressed whether
ubiquitylation may control ICAP-1 functions, enabling the cell to
adapt its migratory response. Here, we show that ICAP-1 is
monoubiquitylated by SMAD ubiquityl regulatory factor 1
(Smurf1). This monoubiquitylation impairs ICAP-1 binding to β1
integrin and is involved in ECMdensity and rigidity sensing aswell as
in coordination of the dynamics of adhesion sites and contractile
machinery. ICAP-1monoubiquitylation plays an important role in the
responses of migrating cells to mechanical inputs in a β1 integrin-
independent manner by promoting the switch from a ROCK2-
mediated to an MRCKα-mediated contractility pathway.
RESULTS
ICAP-1 is monoubiquitylated by Smurf1 at the β1 integrin-
binding site
To investigate ICAP-1 ubiquitylation, we performed nickel-bead
pulldown experiments on Chinese Hamster Ovary (CHO) cells
transfected with ICAP-1 either in the presence or absence of co-
transfection with His-tagged ubiquitin. The proteasome inhibitor
MG132 was added to prevent proteasomal degradation of any
ubiquitylated ICAP-1. When expressed alone, ICAP-1 appeared on
a western blot an apparent molecular mass that was slightly greater
than 20 kDa, whereas co-transfection with His-tagged ubiquitin and
pulldown on nickel beads resulted in isolation of ICAP-1 with
higher molecular mass forms, with a band above 35 kDa (Fig. 1A),
showing that ICAP-1 is indeed ubiquitylated. This band above
35 kDa most likely corresponds to ICAP-1 monoubiquitylation.
HA-tagged ubiquitin (HA–Ubi) was also coexpressed with ICAP-1
fused to Flag and our results show that ICAP-1–Flag can be
recognized by both anti-Flag and anti-HA antibodies after
immunoprecipitation with anti-Flag antibodies (Fig. 1B),Received 28 November 2016; Accepted 8 December 2016
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for Advanced Biosciences, Grenoble 38042, France. 3CNRS UMR 5309, Grenoble
F-38042, France. 4Laboratoire Interdisciplinaire de Physique, UMR CNRS,
Grenoble 5588, France.
*Present address: Cergy Pontoise University, France
‡Author for correspondence (Corinne.albiges-rizo@ujf-grenoble.fr)
H.-N.F., 0000-0002-3918-7330; C.A., 0000-0002-6333-4150
626
© 2017. Published by The Company of Biologists Ltd | Journal of Cell Science (2017) 130, 626-636 doi:10.1242/jcs.200139
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
confirming that ICAP-1 can be ubiquitylated. Furthermore, to
identify which lysine residue is monoubiquitylated, we analyzed
whether truncated forms of ICAP-1 could be monoubiquitylated
(Fig. 1C). We determined that the monoubiquitylation site was
located in the binding domain for β1 integrin. The point mutation of
either one of the two lysine residues present in this domain
identified lysine K158 as the site of monoubiquitylation, as its
replacement with arginine led to the absence of the 35 kDa band
Fig. 1. The Smurf1 ubiquitin ligase is responsible for ICAP-1 monoubiquitylation. (A) ICAP-1 was overexpressed in CHO cells with or without His-tagged
ubiquitin. After pulldown on TALON resin, the ubiquitylated proteins were analyzed by western blotting with the anti-ICAP-1 antibody. ICAP-1 was
monoubiquitylated (Icap-1 Ubi1) and weakly polyubiquitylated (Icap-1 Ubin). (B) ICAP-1–Flag immunoprecipitated by anti-Flag antibody can be recognized by
anti-HA antibodies (as assessed bywestern blotting) after co-transfection with HA–Ubi and ICAP-1–Flag in CHO cells. The results are representative of more than
three independent experiments. (C) Different ICAP-1 constructs were used to identify the ubiquitylated lysine residue. The horizontal-striped box corresponds
to the β1 integrin-binding site. (D) ICAP-1 WT, ICAP-1 K152R or ICAP-1 K158R were overexpressed in CHO cells with His-tagged ubiquitin. His-tagged
pulldown assays show that only the ICAP-1 K158Rmutant was not monoubiquitylated. The results are representative of three independent experiments. (E) HeLa
cells with or without Smurf1 knockdownwere co-transfected with ICAP-1 andHis-tagged ubiquitin. After pulldown on TALON resin, the ubiquitylated proteins were
analyzed by western blotting with the anti-ICAP-1 antibody. Non-ubiquitylated ICAP-1 was used to ensure equivalent ICAP-1 levels in both lysates. CT, control.
(F) Quantification of the level of ubiquitylated ICAP-1 in Smurf1-silenced HeLa cells. Error bars represent s.e.m. (n=3). PM, position of molecular mass makers.
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(Fig. 1D) without changing the ICAP-1 polyubiquitylation states
(Fig. 1D). The non-ubiquitylable K158R mutant was even less
stable than wild-type (WT) ICAP-1, suggesting that the
monoubiquitylated form of ICAP-1 is not targeted for
proteasomal degradation but rather may have a signaling function
(Fig. S1A,B). Because Smurf1 catalyzes the ubiquitylation of the
integrin activator talin (Huang et al., 2009), we hypothesized that
Smurf1 could be responsible for ICAP-1 monoubiquitylation. To
test this hypothesis, Smurf1 was silenced by small interfering RNA
(siRNA); there was a high efficiency in reducing Smurf1 transcript
and protein levels without affecting ICAP-1 expression (Fig. 1E).
ICAP1monoubiquitylation was blocked when Smurf1 was knocked
down, suggesting that Smurf1 is necessary for promoting ICAP-1
monoubiquitylation (Fig. 1E,F). A pulldown assay shows that
purified recombinant Smurf1–GST is able to bind to exogenously
expressed ICAP-1 in CHO cells, in contrast to the null interaction
with GST alone (50-fold less) or with the weak binding to GST
fused to Smurf2 (10-fold less) (Fig. S1C). Smurf2 had been chosen
as a control because overlapping but distinct substrate and regulator
specificity has been observed between Smurf1 and Smurf2 (Lu
et al., 2008, 2011). The co-immunoprecipitation between Smurf1–
Myc and ICAP-1–Flag expressed in CHO cells confirms that
Smurf1 and ICAP-1 belong to the same complex (Fig. S1D). A
direct interaction between Smurf1 and ICAP-1 was demonstrated
by an ELISA assay using purified recombinant GST–Smurf1 and
purified recombinant ICAP-1–His (Fig. S1E). Taken together, our
results indicate that Smurf1 is responsible for ICAP-1
monoubiquitylation.
The monoubiquitylation of ICAP-1 prevents binding to β1
integrin and regulates β1 integrin-dependent adhesion
According to structure predictions and crystallographic data (Chang
et al., 2002; Liu et al., 2013), the monoubiquitylation site is located
in the β1 integrin-binding domain of ICAP-1 facing the isoleucine
residue important for the binding to β1 integrin (Fig. 2A). As this
monoubiquitylation could interfere with the interaction between
ICAP-1 and β1 integrin, we used two classical methods to produce
an ubiquitylated form of a protein (Torrino et al., 2011; Visvikis
et al., 2008), first by co-transfecting ICAP-1 with His-tagged
ubiquitin and second by creating a chimera made of ubiquitin
fused to the C-terminal tail of ICAP-1 (ICAP-1–Ubi) (Fig. 2B).
We tested the ability of WT, non-ubiquitylatable (K158R) and
monoubiquitylated ICAP-1 (endogenous ubiquitylation or chimera)
to interact with the cytoplasmic domain of either β1 integrin or β3
integrin fused with GST or with GST alone by pulldown assay
(Fig. S2A) or by ELISA assay (Fig. 2C). As previously reported
(Millon-Frémillon et al., 2008), we confirmed that ICAP-1
specifically interacts with the cytoplasmic domain of β1 integrin
(Fig. 2C; Fig. S2A). Furthermore, the non-ubiquitylated K158R
mutant retained the ability to interact with the cytoplasmic domain
of β1 integrin, whereas both ubiquitylated forms of ICAP-1
(His-tagged and chimeric) lost the capacity to interact with
the cytoplasmic domain of β1 integrin (Fig. 2C; Fig. S2A). These
results show that ICAP-1 monoubiquitylation prevents the
interaction of ICAP-1 with β1 integrin.
Next, we investigated whether the monoubiquitylation of
ICAP-1 could affect FA organization by rescuing ICAP-1-deficient
osteoblast cells with a similar stable expression of WT ICAP-1, non-
ubiquitylatable ICAP-1 K158R and of the chimeric ubiquitylated
form. All osteoblast cell lines were able to spread onto FN and
develop FAs containing β1 integrins, as revealed by 9EG7 antibody
staining for activated β1 integrin (Fig. 2D). Like ICAP-1-deficient
cells, cells expressing the ubiquitylated form of ICAP-1 displayed
more numerous β1 integrin-containing FAs compared with cells
expressing the WT form (Fig. 2D–F) because of the inability of the
monoubiquitylated ICAP-1 to inhibit β1 integrin. Conversely, cells
expressing the non-ubiquitylatable ICAP-1 K158R mutant
displayed fewer, smaller and more-punctate adhesion sites
(Fig. 2D–F) compared with those of WT ICAP-1, likely due
to its ability to interact with β1 integrin and thus inhibit the
assembly of larger FAs (Bouvard et al., 2007; Millon-Frémillon
et al., 2008).
As Smurf1 is responsible for ICAP-1 monoubiquitylation, we
investigated whether the formation of β1 integrin-containing FAswas
dependent on Smurf1 activity. As expected, the deletion of Smurf1
led to a decrease in the number and area of β1 integrin-containing FA
(Fig. S2B,C,D) phenocopying the non-ubiquitylatable ICAP-1
K158R phenotype (Fig. 2D–F). Conversely, the ubiquitylated
ICAP-1 was able to bypass the destructive effect of Smurf1
deletion on β1 integrin-containing FAs (Fig. S2B,C,D). Thus,
Smurf-1-mediated ICAP-1 monoubiquitylation plays a crucial role
in the organization of β1 integrin-containing FA by preventing or
disrupting the ICAP-1–β1-integrin interaction.
ICAP-1 monoubiquitylation is a signal coordinating FN
density sensing with rigidity sensing
Wewondered whether ICAP-1 monoubiquitylation was involved in
FN density and rigidity sensing. To test an effect on FN density
sensing, single-cell tracking of sparse cells was performed to
monitor the migration speed of ICAP-1-deficient osteoblast or
mouse embryonic fibroblast (MEF) cells expressing WT ICAP-1,
K158R ICAP-1 or ICAP-1–Ubi in the presence of increasing
concentrations of FN. As expected (Discher et al., 2005; Engler
et al., 2006; Raab et al., 2012), WT ICAP-1-expressing osteoblasts
(Fig. 3A; Movies 1,2) or MEFs (Fig. S3A) displayed faster
migration rates with increasing FN density. While the migratory
speed of the cells expressing the ubiquitylated ICAP-1 form
depended on ECM density, like ICAP-1 null cells, the cells
expressing the non-ubiquitylatable K158R mutant maintained the
same migration speed whatever the density of FN coating (Fig. 3A;
Fig. S3A, Movies 3,4). Moreover, the ability to adapt their
migration response to ECM density was lost in cells treated with
siRNA against Smurf1 but was rescued in cells co-expressing the
monoubiquitylated ICAP-1 showing that the Smurf1-dependent
monoubiquitylation of ICAP-1 is necessary for cells to sense and
respond to FN density (Fig. S3B).
To explore the possibility that the inability of the K158R mutant
to adapt its migration speed to FN density could be due to a greater
capacity to lock β1 integrin in its inactivated form than with WT
ICAP-1, we analyzed the response of cells treated with β1 integrin-
blocking antibodies to increasing FN density. We showed that
these cells were unable to sense the density of FN or adapt their
migratory behavior (Fig. 3B), confirming the requirement for β1
integrin activation for the adaptation of the cell migration rate to the
FN density. Additionally, cells co-expressing a β1 integrin mutant
that lacks ICAP-1 binding (β1 V787T) with the ICAP-1 K158R
mutant or in the context of silenced Smurf1 were still able to adapt
their migration speed to the FN density (Fig. 3B; Fig. S3C).
Therefore, the unresponsiveness of cells to the FN density is most
likely due to the inhibitory interaction between the non-
ubiquitylatable ICAP-1 and β1 integrin. Overall, ICAP-1
monoubiquitylation by Smurf1 is required to release ICAP-1
inhibitory effect on β1 integrin in order to permit the adaptation of
cell migration to ECM density.
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Fig. 2. Ubiquitylated ICAP-1 does not interact with the β1 integrin cytoplasmic tail and disorganizes FA distribution. (A) Recently published structure of
ICAP-1 interacting with the β1 integrin cytoplasmic tail (PDB 4DX9) (Liu et al., 2013). Blue, ICAP-1 protein with I139 represented in yellowandK158 represented in
red. Orange, β1 integrin cytoplasmic tail. This image was made with VMD, NAMD, BioCoRE, JMV and other software support (these software packages are
developed with NIH support by the Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign).
(B) ICAP-1 constructs used for the study. K158R is the non-ubiquitylatable form. ICAP-1–His–Ubi results from the overexpression of ICAP-1 and His-tagged
ubiquitin proteins in CHO cells. ICAP-1–Ubi is a chimeric form with ubiquitin fused at the C-terminus of ICAP-1 to mimic constitutive monoubiquitylation.
(C) Interaction between recombinant ICAP-1–His or ICAP-1–Ubi–His and recombinant GST or the GST–β1 integrin cytoplasmic domain as determined by an
ELISA assay. The results are representatives of three independent experiments. (D) β1 integrin staining in ICAP-1-null osteoblasts or ICAP-1-null cells rescued
with ICAP-1 WT, non-ubiquitylatable ICAP-1 or the ICAP-1 ubiquitin chimera spread on FN for 2.5 h. The cells expressing the non-ubiquitylatable form (K158R)
display smaller β1 integrin FAs comparedwith the cells expressing ICAP-1WT. Scale bars: 10 μm. (E) Quantification of the β1 integrin focal adhesion number and
(F) distribution of the β1 integrin focal adhesion areas. Analyses were performed on 30–40 cells from two independent experiments. Error bars indicate s.e.m.
*P<0.05, ***P<0.0005 (one-way ANOVA and Tukey’s HSD test).
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We next evaluated the effects of ICAP-1 monoubiquitylation on
the ECM rigidity sensitivity. Osteoblast cells (Fig. 3C) or MEF cells
(Fig. S3D) infected with ICAP-1WT, ICAP-1 K158R and ICAP-1–
Ubi were plated onto FN-conjugated elastomeric polyacrylamide
(PAA) gels with increasing Young’s modulus (E) and monitored for
cell migration. As expected, the WT ICAP-1 cells moved more
quickly on stiffer gels than they did on softer gels (40% increase on
the stiffer substrate) (Fig. 3C; Fig. S3D, Movies 5,6). Cells
expressing ICAP-1 K158R still responded to the increase in matrix
rigidity, whereas cells expressing the monoubiquitylated ICAP-1
displayed a constant migration velocity that was independent of the
stiffness of the substrate, like ICAP-1-deficient cells (Fig. 3C;
Fig. S3D, Movies 7,8). However, the migration speed of ICAP-1−/−
cells was slightly but significantly higher as compared to that of
ICAP-1–Ubi cells. This suggests that ICAP-1 monoubiquitylation
also controlled the capacity of cells to adapt their velocity to ECM
rigidity. As monoubiquitylation prevents ICAP-1 and β1 integrin
interaction, we then investigated whether rigidity sensing was
dependent on ICAP-1 and β1 integrin interaction. Cells expressing
the β1 integrin V787T mutant that are unable to interact with ICAP-
1 still adapt their velocity in response to the external rigidity
(Fig. 3D) whereas ICAP-1 deficiency led to insensitiveness to
substrate stiffness (Fig. 3C). Thus, the presence of ICAP-1 is
required even though ICAP-1 interaction with β1 integrin is
dispensable for rigidity sensing. Monoubiquitylation of ICAP-1 is a
signal that allows the sensing of matrix density and rigidity by
Fig. 3. ICAP-1 ubiquitylation controls FN density and rigidity sensing. Osteoblasts were spread on increasing concentrations of FN and migration was
monitored for 5 h using time-lapse microscopy. Cell velocity was determined by individually tracking 150–200 cells from three independent experiments. (A) Cells
expressing ICAP-1-WT, the ICAP-1 ubiquitin chimera or cells deficient in ICAP-1 adapted their migratory speed according to the FN density, whereas the
cells expressing the ICAP-1 K158R mutant maintained the same speed regardless of the FN density. (B) Similar to the cells expressing ICAP-1 K158R, cells
treated with a blocking anti-β1 integrin antibody (Ab Ha2/5) were unable to adapt their migration speed to the FN density. β1 integrin-null cells expressing the
β1 integrin mutant that lacks ICAP-1 binding (V787T) were not affected by K158R ICAP-1 expression. (C,D) Osteoblast cells were spread on FN-coated PAA
gels of different rigidities. Cell migration was monitored for 5 h using time-lapse microscopy. The cell velocity was determined by individually tracking
150–300 cells in three independent experiments. Similar to in ICAP-1-deficient cells, ICAP-1–Ubi cells did not change their velocity according to gel rigidity
whereas WT cells moved more quickly in stiffer gels (C). β1 integrin-null cells expressing the β1 integrin mutant that lacks ICAP-1 binding (V787T) responded to
gel rigidity similarly to control cells (D) indicating that the interaction between β1 integrin and ICAP-1 is not necessary to adapt cell migration to substrate stiffness.
Error bars indicate the mean±s.e.m. *P<0.05, **P<0.005, ***P<0.0005 (one-way ANOVA and Tukey’s HSD test).
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decoupling the inhibitory role of ICAP-1 on β1 integrin from an
unexpected role that is independent of its interaction with β1
integrin.
The monoubiquitylation of ICAP-1 increases cell
contractility
As rigidity sensing is associated with cell contractility, we sought to
determine whether the monoubiquitylated form of ICAP-1 might
interfere with cell contractility. First, as a contractility marker, we
analyzed the phosphorylation state of myosin light chain (pMLC)
by western blotting lysates fromWT, and ICAP-1–Ubi and ICAP-1-
deficient cells plated onto FN-coated plastic or elastomeric PAA
gels with a Young’s modulus (E) of 4 or 50 kPa (Fig. S4A). As
expected, the level of pMLC in total cell lysates of cells expressing
ICAP-1 WT increased with the substrate rigidity. ICAP-1-deficient
cells displayed the same behavior as ICAP-1 WT cells. In contrast,
cells expressing the monoubiquitylated ICAP-1 showed a constant
level of pMLC independently of the rigidity of the substrate. This
loss of pMLC regulation is correlated with the inability of ICAP-1–
Ubi cells to adapt their velocity to ECM rigidity (Fig. 3C). In
addition, an increase of pMLC staining along the stress fibers in
ICAP-1–Ubi cells was noted (Fig. 4A). To investigate whether the
monoubiquitylated ICAP-1 is involved in the genesis and
modulation of forces applied to the substratum, traction force
microscopy (TFM) was used. Traction forces generated by
the cells were twice as high in ICAP-1–Ubi cells as compared to
the WT cells and ICAP-1-deficient cells (Fig. 4B). Therefore, the
monoubiquitylation of ICAP-1 increases cell contractility by
forcing the phosphorylation of myosin independently of the
substrate rigidity.
The monoubiquitylation of ICAP-1 drives MRCKα-mediated
cell contractility
Cell contractility relies on the balance between ROCK, MLCK and
mDia activities to control elongation and organization of actin
filament (Burridge andWittchen, 2013). To explore the contractility
pathways potentially affected by ICAP-1–Ubi, a pharmacological
approach was used by testing ROCK, MLCK and mDia inhibitors
(Y27632, ML7 and SmifH2, respectively) on the migration of
osteoblasts adhered to 4 kPa gels coated with 5 μg/ml of FN. Like
WT cells, ICAP-1–Ubi cells migrated slower upon MLCK and
mDia inhibition (Fig. S4B). As previously described (Totsukawa
et al., 2000), WT cells migrate faster upon ROCK inhibition. In
contrast, ICAP-1–Ubi cells were insensitive to Y27632 treatment
since no change in migratory speed response was observed as
compared with theWT cells (Fig. S4B). This insensitivity to ROCK
inhibition in ICAP-1 Ubi cells is not due to the loss of the interaction
between ICAP-1–Ubi and β1 integrin since cells expressing the
V787Tmutant of β1 integrin, which is unable to interact with ICAP-
1, are still sensitive to ROCK inhibition (Fig. S4C). Thus, ICAP-1–
Ubi cell migration is independent of ROCK-controlled contractility,
suggesting an alternative contractile pathway for ICAP-1–Ubi cells.
Besides regulating ROCK1 (Peter et al., 2006), ICAP-1 has been
shown to inhibit Cdc42 and Rac1 (Degani et al., 2002), which are
involved in the regulation of MRCK. Therefore, we sought to assess
whether ICAP-1 could regulate MRCK-dependent cell contractility
(Leung et al., 1998). To test this hypothesis, we used a siRNA
strategy to knockdown ROCK1, ROCK2, MRCKα and MRCKβ
(Fig. 4C,D). The WT ICAP-1 cells moved more quickly on stiffer
gels than they did on softer gels whatever the siRNA used except in
conditions of ROCK2 deletion suggesting that WT cells adapt their
migratory behavior through a ROCK2-dependent contractility and
this behavior is independent of ROCK1, MRCKα and MRCKβ
(Fig. 4C). In contrast, only MRCKα silencing in ICAP-1–Ubi cells
led to an increase in the cell migration speed when rigidity of the
substrate was increased (Fig. 4D). Thus, the cell contractility mode
imposed by ICAP-1 monoubiquitylation is dependent on MRCKα
and is independent of ROCK1, ROCK2 and MRCKβ. To confirm
the involvement of MRCKα in the monoubiquitylated ICAP-1-
dependent phosphorylation of myosin, we tested the effect of
siRNA againstMRCKα or ROCK2 on the decoration of stress fibers
by T18/S19 phosphorylated MLC (ppMLC) (Fig. 4E). Whereas the
siRNA against ROCK2 decreased the level of ppMLC in WT cells,
the depletion of MRCKα significantly reduced the level of
ppMLC in cells infected with ICAP-1–Ubi. Thus, ICAP-1
monoubiquitylation favors the phosphorylation of myosin II that
is dependent on the activity of MRCKα whereas ROCK2 activity is
responsible for the phosphorylation of myosin II in WT cells. Taken
together, these results show that ICAP-1 monoubiquitylation allows
the switch from ROCK2-mediated to MRCKα-mediated cell
contractility.
DISCUSSION
Our data show that monoubiquitylation of ICAP-1, a protein that
associates with integrin cytoplasmic domains, by Smurf1 is
involved in regulating the balance between adhesion and
contractility. ICAP-1 monoubiquitylation inhibits its binding to β1
integrin, subsequently regulating the number and organization of β1
integrin-containing FAs. ICAP-1 and its monoubiquitylated form
may be crucial mediators involved in the balance between ROCK2
and MRCKα activities in order to adapt cell contractility to the
variability of ECM stiffness. Our results show that these two
functions of ICAP-1 are integrated by the cell to sense both matrix
density and rigidity.
Smurf1 asanode tocontrol focal adhesiondynamicsandcell
contractility
In addition to its ability to ubiquitylate talin (Huang et al., 2009),
Smurf1 was a good candidate for ICAP-1 monoubiquitylation
because Smurf1 associates with the cerebral cavernous
malformations (CCM) complex (Crose et al., 2009), which
interacts with ICAP-1 (Hilder et al., 2007). Smurf1 also possesses
an NPxY motif that might be able to interact with ICAP-1
phosphotyrosine-binding (PTB) domain. Smurf1 is also involved in
cell polarity and cell migration (Sahai et al., 2007; Wang et al.,
2003). We demonstrated that the monoubiquitylation of ICAP-1 by
Smurf1 is not involved in ICAP-1 degradation via the proteasome,
but rather, regulates the assembly and organization of FAs by
modulating the ICAP-1–β1-integrin interaction. The ICAP-1–β1-
integrin interface is likely disrupted upon ICAP-1
monoubiquitylation since K158 is in close vicinity to the I138
residue known to be important for the β1 integrin interaction (Chang
et al., 2002; Liu et al., 2013).
In addition to their canonical roles in cell growth and
differentiation mediated through TGF signaling (Zhu et al., 1999),
accumulating evidence indicates that Smurfs play key roles in
regulating cell adhesion and migration. Smurf1 is localized in
lamellipodia and filopodia, with a fraction of Smurf1 in FAs (Huang
et al., 2009; Wang et al., 2003). Smurf1 ubiquitylates molecules
involved in both cell adhesion and contractility. Smurf1 controls
talin head degradation, and subsequently adhesion stability and cell
migration (Huang et al., 2009). RhoA ubiquitylation by Smurf1
causes its degradation at the leading edge of migrating cells and
promotes lamellipodium formation (Sahai et al., 2007; Wang et al.,
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Fig. 4. See next page for legend.
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2003). Our data demonstrate that Smurf1 is a node controlling both
FA dynamics and cell contractility through a common target,
ICAP-1. ICAP-1 monoubiquitylation not only regulates the number
and organization of β1 integrin-containing FAs but also inhibits
ROCK signaling and promotes the MRCK signaling pathway.
Therefore, we add another piece of evidence showing that the
RhoA–ROCK pathway is inhibited by Smurf1, and we demonstrate
for the first time that Smurf1 controls a switch from a ROCK-
dependent to a MRCK-dependent cell contractility.
The monoubiquitylation of ICAP-1 as a switch from ROCK2-
mediated to MRCKα-mediated contractility
In addition to its role in the β1 integrin activation cycle (Millon-
Frémillon et al., 2008), ICAP-1 interferes with small GTPase
signaling and cell contractility by putting a cap on RhoA activation
(Faurobert et al., 2013) and inhibiting Rac1 and Cdc42 (Degani
et al., 2002). So far, how ICAP-1 can regulate both RhoA–ROCK
signaling and the Cdc42 and Rac1 pathway was unclear. It has been
described that a cooperation between RhoA–ROCK and Cdc42 or
Rac1–MRCK signaling can control cell contractility cell polarity,
morphology and morphogenesis (Gally et al., 2009; Unbekandt and
Olson, 2014; Wilkinson et al., 2005). Their respective contribution
might depend on ECM rigidity. ICAP-1, independently of its
interaction with β1 integrin, could act as a sensor of ECM rigidity
differently modulating the activity of each enzyme depending on the
substrate stiffness. It could act by playing on the level of activation
of RhoA, Rac1 or Cdc42 and by directly modulating the activity
of ROCK2 and MRCKα. Thus, we propose that ICAP-1
monoubiquitylation by Smurf1 is a key event leading to a switch
from ROCK2-mediated to MRCKα-mediated cell contractility.
ICAP-1 and its monoubiquitylated form regulate ROCK2- and
MRCKα-dependent MLC phosphorylation independently of
interaction with β1 integrin. This is in line with previous studies,
which do not attribute a major role of β1 integrin to ECM rigidity
sensing (Jiang et al., 2006). Taken together, our results show that
ICAP-1 contributes to an elaborate signaling network responsible
for maintaining cell tensional homeostasis, going from the
dynamics of cell adhesion to the adaptation of contractile
actomyosin machinery. ICAP-1 may function in β1 integrin-
dependent and -independent pathways to orchestrate both the
chemo and mechanical regulation of cell migration. These two
pathways might regulate distinct signaling cascades through a
switch operated by Smurf1 to adapt the cellular migratory response
(Fig. 5). ICAP-1 is essential in rigidity sensing and its
monoubiquitylation might be crucial for the adaptation of cells to
a local variation of ECM stiffness in tissues or a change of ECM
composition during development or in pathological situations.
ICAP-1 monoubiquitylation would allow the cell to adapt its the
contractility depending on substrate stiffness by controlling the
balance between ROCK2-and MRCKα-mediated cell contractility.
In future studies, it will be important to identify the factors that are
regulated by ICAP-1 independently of its interaction with β1
integrin in order to develop a more complete understanding of the
functions of ICAP-1 in mechanosensing.
MATERIALS AND METHODS
Plasmid construction
The plasmids pCMVFlag-Smurf1 WT, pGEX4T1-Smurf1 WT, pGEX4T1-
Smurf2 WT, pRK5-Myc-Smurf1 and pRK5-HA-Ubiquitin-WT were
obtained from Addgene (Cambridge, MA; numbers 11752, 13502,
13504, 13676 and 17608). pGEX4T1 plasmids containing the β1 or β3
integrin cytoplasmic domain, as well as pCLMFG retroviral vectors
containing WT β1 integrin or the V787T mutant, have been previously
described (Brunner et al., 2011). The pSG5-ubiquitin-His vector was a kind
gift from Saadi Khochbin (U823 INSERM-UJF, Grenoble, France). The
full-length cDNA of WT human ICAP-1 was subcloned into the EcoRI
and BamHI sites of the pBabe-puro retroviral vector (pBabe-ICAP-1 WT).
The K158R substitution was introduced into the ICAP-1 cDNA via site-
directed mutagenesis (pBabe-ICAP-1 K158R). The Myc tag was inserted at
the 3′ end of the ICAP-1 or ubiquitin cDNA using PCR. The Myc-tagged
ICAP-1 cDNA was subcloned between the BamHI and EcoRI sites of the
pcDNA3.1 expression vector and mutated to generate the K158R mutant.
Fig. 4. The monoubiquitylation of ICAP-1 drives an MRCKα-mediated cell
contractility. (A) Immunostaining of ppMLC and actin (phalloidin) in WT cells
and ICAP-1–Ubi osteoblast cells. Note the increase of ppMLC along the stress
fibers as seen from the quantification of 80 cells from three independent
experiments. (B) Representative traction forcemaps obtained by TFM in ICAP-
1 WT, ICAP-1-deficient and ICAP-1–Ubi osteoblast cells (images). TFM
experiments showed an increase of the force applied on the substrate in ICAP-
1–Ubi cells as compared to ICAP-1 WT and ICAP-1-deficient cells (n=78 from
three independent experiments) (graph). Error bars indicate the mean±s.e.m.
***P<0.0005 (one-way ANOVA and Tukey’s HSD test). (C) Osteoblasts were
spread on FN-coated PAA gels of different rigidities. Cell migration was
monitored for 5 h using time-lapse microscopy. Cell velocity was determined
by individually tracking 200–300 cells in three independent experiments.
Monitoring of WT cells migration after treatment with scrambled siRNA (siRNA
CT) or siRNA against ROCK1, ROCK2, MRCKα or MRCKβ on 4 or 50 kPa
gels. Note that WT cells are sensitive to ROCK2 siRNA treatment.
(D) Monitoring of ICAP-1–Ubi osteoblast cells migration after treatment with
scrambled siRNA (siRNACT) or with siRNA against ROCK1, ROCK2, MRCKα
or MRCKβ on 4 or 50 kPa gels. Note that ICAP-1–Ubi cells are sensitive to
MRCKα siRNA treatment. (E) Immunostaining of ppMLC in WT osteoblast
cells and ICAP-1–Ubi osteoblast cells after treatment with siRNA against
ROCK2 or MRCKα (left panel). The right-hand panel shows a quantification of
ppMLC staining. Note the decrease of ppMLC staining along the stress fibers
after siRNA against ROCK2 for the WT cells whereas the decrease of ppMLC
is observed after treatment with siRNA against MRCKα for ICAP-1–Ubi cells
(n>80). Error bars indicate the mean±s.e.m. *P<0.05; ***P<0.0005; NS, not
significant (one-way ANOVA and Tukey’s HSD test). Scale bars: 10 μm.
Fig. 5. A ROCK2–MRCKα switch operated through the
monoubiquitylation of ICAP-1 by Smurf1 to adapt the
cellular migratory response. Smurf1 is able to
monoubiquitylate ICAP-1. The monoubiquitylation of
ICAP-1 by Smurf1 is required to release inhibitory effect of
ICAP-1 on β1 integrin, thereby facilitating the activation–
deactivation cycle of β1 integrin important for ECM density
sensing and adaptive cell migration responses. The
monoubiquitylation of ICAP-1 allows the switch from
ROCK2-mediated to MRCKα-mediated cell contractility to
control ECM rigidity sensing.
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The cDNA of Myc-tagged ubiquitin was amplified and inserted at the 3′
end of the ICAP-1 cDNA, between the EcoRI and XhoI sites of the
pcDNA3.1 vector (pcDNA3.1-ICAP-1-myc, pcDNA3.1-ICAP-1 K158R-
myc and pcDNA3.1-ICAP-1-Ubi-myc). The ICAP-1-Ubi-myc cDNA was
subcloned into the pBabe-puro, between the BamHI and SalI sites (pBabe-
ICAP-1-Ubi-myc).
Cell culture, transfection and antibodies
Immortalized osteoblasts were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Life Technologies, Cergy Pontoise, France),
CHO cells and HeLa cells were grown in αMEM (PAA) at 37°C in a
humidified, 5% CO2 chamber. All media are supplemented with 10% fetal
calf serum (FCS; Invitrogen), 100 U/ml penicillin and 100 μg/ml
streptomycin. Immortalized osteoblasts from icap-1−/−; Itgb1 flox/flox mice
were generated as previously described (Bouvard et al., 2007). These cells
were treated with or without adenoCre viruses obtained from the gene
transfer vector core (University of Iowa) to generate β1 integrin-null cells.
The ICAP-1-null cells were incubated with or without retroviral particles to
obtain rescued cells expressing ICAP-1WT, ICAP-1 K158R or the ICAP-1–
Ubi chimera. The cells were selected with 1 mg/ml puromycin to produce
cell populations with heterogeneous ICAP-1 expression levels. β1 integrin-
null cells that had already been rescued with ICAP-1 were again infected
with retrovirus to obtain double-rescued cells expressing ICAP-1 (WT or
mutant) andWT β1 integrin or the V787T mutant. For all experiments, cells
were trypsinized and washed in PBS before plating in DMEM containing
4% FN-free FCS for 3 h. Osteoblasts (90×104 cells) were transfected with
25 pmol siRNA and 6 μl Lipofectamine RNAiMAX reagent (Invitrogen)
according to the manufacturer’s instructions. The cells were used 2 days
after transfection. SMARTpool siRNA (Dharmacon Research Inc.,
Lafayette, LA) was used against appropriate proteins, along with the
control siRNA sequence 5′-AGGUAGUGUAAUCGCCUUG-3′. HeLa
cells were transfected with control or Smurf1 siRNA SMARTpool siRNA
(Dharmacon Research Inc.) using Lipofectamine RNAiMAX (Invitrogen)
according to the manufacturer’s instructions; two rounds of transfection
were performed. ICAP-1 and His-tagged ubiquitin were overexpressed
using Fugene (BD Biosciences, Le Pont de Claix, France) according to the
manufacturer’s instructions. CHO cells were transfected with ExGen
(EUROMEDEX, Souffelweyersheim, France) following the manufacturer’s
instructions using pcDNA3.1-ICAP-1-myc, pcDNA3.1-ICAP-1K158R-
myc or pcDNA3.1-ICAP-1-Ubi-myc. CHO cells were cotransfected with
pcDNA3.1-ICAP-1-myc or pcDNA3.1-ICAP-1 K158R-myc and pSG5-
ubiquitin-His. After 24 h, the transfected cells were incubated with the
proteasome inhibitor MG132 (20 μM) for 4 h. The antibodies used in this
study were the following: rat anti-β1 integrin 9EG7 (1:100; BDBiosciences,
553715), donkey anti-rabbit-IgG conjugated to HRP (1:12,000; Jackson
ImmunoResearch, UK, 711-036-152), goat anti-rat-IgG conjugated to Alexa
Fluor 488 (1:1000; Invitrogen, A-11006), mouse anti-actin (1:1000; Sigma-
Aldrich, Saint Quentin Fallavier, France, A2066), mouse anti-Smurf1
(1:1000; Santa Cruz Biotechnology, Heidelberg, Germany, Sc-100616)
rabbit anti-T18/S19 MLC [1:1000 (western blotting) or 1:100
(immunofluoresence); Cell Signaling Technology, Leiden, The
Netherlands], and rabbit anti-ICAP-1 (1:1000; Millon-Frémillon et al.,
2008).
Purification of His-tagged ubiquitylated proteins
Transfected CHO cells were lysed in phosphate-buffered saline (PBS)
containing 10%glycerol, 0.3%NP40, 5 mMNEM, 10 mMNaF, phosphatase
inhibitor cocktails 2 and 3 (Sigma-Aldrich), and a protease inhibitor cocktail
(cOmplete, EDTA-free, Roche, Meylan, France). After centrifugation
(15,000 g for 20 min), the supernatants were incubated with Talon Metal
Affinity resin (Clontech, Saint Germain en Laye, France) for 2 h. After three
washes, the proteins were eluted in Laemmli buffer and analyzed by western
blotting (3% of the total lysate is used for the input track).
Pulldown assays
GST–Smurf1 and GST–Smurf2 were expressed in E. coli (BL21 DE3 RIL)
as previously described (Wang et al., 2006). Transfected CHO cells were
lysed in buffer containing 50 mM Tris-HCl pH 7.7, 150 MG132, protease
inhibitor cocktail and phosphatase inhibitor cocktails 2 and 3. The
supernatants were incubated for 3 h with GST–Smurf1-, GST–Smurf2- or
GST-coupled glutathione–Sepharose beads. After five washes in lysis
buffer, the samples were eluted in Laemmli buffer and analyzed by western
blotting (3% of the total lysate is used for the input track). GST–β1-integrin
and GST–β3-integrin were expressed in E. coli (BL21 DE3 RIL), and
pulldown experiments with supernatants from transfected CHO cells were
performed as previously described (Brunner et al., 2011).
ICAP-1 protein lifetime measurement
Transfected CHO cells were incubated with 100 μg/ml cycloheximide
(Sigma-Aldrich) with or without 20 μM MG132. Cells were lysed in RIPA
buffer at the indicated times, and the protein concentration was measured
using the BCA assay. Total proteins (20 μg) were separated by SDS-PAGE
and immunoblotted as below.
Flag immunoprecipitation
Transfected CHO cells were lysed in lysis buffer (50 mM NaCl, 10 mM
Pipes, 150 mM sucrose, 50 mM NaF, 40 mM Na4P2O7·10H2O, 1 mM
Na3VO4, pH 6.8, 0.5% Triton X-100, 0.1% sodium deoxycholate, and
protease inhibitor cocktail). The supernatants were incubated for 1 h with
anti-Flag M2 magnetic beads (Sigma-Aldrich). After four washes with lysis
buffer, the samples were eluted in lysis buffer containing 100 μg/ml Flag
peptide (Sigma-Aldrich) and analyzed by western blotting (3% of the total
lysate is used for the input track).
ELISA assay
The interaction between recombinant ICAP-1 and ICAP-1–Ubi was
analyzed using a solid-phase assay. Briefly, a 96-well tray (MaxiSorp,
Nunc) was coated with either ICAP-1-His or ICAP-1–Ubi–His (40 μg/ml)
for 16 h at 4°C and blocked with 3% BSA in PBS for 1 h at room
temperature. Increasing concentrations of GST, the GST–β1-integrin
cytoplasmic domain or GST–Smurf1 were added for 1 h. After three
washes in PBS with 0.1% Tween20, detection of bound proteins was
performed by using the antibodies directed against β1 integrin cytoplasmic
domain or Smurf1. Nonspecific binding to BSA-coated wells was
subtracted from the results as background.
pMLC western blot analysis
Cells were plated on plastic or on PAA gels with controlled rigidities of 50
kPa or 4 kPa (Cell Guidance System, Cambridge, UK) coated with 1 μg/cm2
(5 μg/ml) of FN. The next day cells were lysed in Laemmli buffer and
analyzed by western blotting. Immunoblots were visualized using the ECL
system (Biorad) and Chemidoc imaging system (Biorad).
Traction force microscopy
The PAAsubstrates were prepared on two-well LabTek slides (Thermo Fischer
Scientific, Ulm, Germany) using 8% acrylamide mixed with appropriate
percentage of bis-acrylamide and 10 mM HEPES (pH 8.5) gels. After two
Sulfo-SANPAH (Thermo Fischer Scientific, Ulm, Germany) activations, the
gels were coated with 5 μg/ml FN (1 μg/cm²) at 4°C overnight. We used a
concentration of 0.15% of bis-acrylamide to create gels with controlled
rigidities of 5 kPa. Cells were plated at an approximate density of 2×104 cells
per cm2 for 3-4 h and images were acquired on an iMIC Andromeda
(FEI, Gräfelfing, Germany) microscope at 40x magnification. Force
calculations were performed as previously described (Tseng et al., 2011).
Random migration analysis
Cells were plated on a 12-well plate containing a PAA substrate (Cell
Guidance System) or on an 8-well LabTek slide coated with various FN
concentrations at an approximate density of 1.2×105 per cm2 for 3 h in CO2-
independent DMEM containing 4% FN-free FCS. The cells were
maintained at 37°C and imaged on an inverted microscope (Zeiss
Axiovert 200) equipped with a motorized stage, cooled CCD camera
(CoolSnap HQ2, Roper Scientific) and a 10× objective (EC Plan-Neofluar)
for live-cell imaging for 5 h at a frequency of 1 image every 4 min. Inhibitors
were added as indicated to the medium 10 min prior to the initiation of
image acquisition and maintained throughout the migration assay at a final
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concentration of 10 μM for Y27632 (Calbiochem), 5 μM for ML7
(Calbiochem) and 2 μM for SmifH2 (Calbiochem). Cell velocity was
obtained using the manual tracking plug-in in ImageJ software. A total of
150–300 cells were analyzed from at least five different locations in each
experiment, and results were collected from three independent experiments.
Immunofluorescence
Cells were plated at an approximate density of 2×104 cells per cm2 for 2.5 h in
24-well plates on slides coated with 0.6 μg/cm2 (2 μg/ml) or 1.5 μg/cm2
(5 μg/ml) of FN in DMEM containing 5% FN-depleted serum; the cells were
then fixed and immunostained as previously described (Millon-Fremillon
et al., 2008). For the focal adhesion analysis, imageswere acquired on anAxio
Imager (Zeiss) microscope at with a 63× objective. We analyzed the β1
integrin staining of 30–40 cells from two independent experiments using a
thresholding method and the particle analyzer in ImageJ. Particles larger than
0.5 μm2 were analyzed. Internal focal adhesions are defined as a FA that was
more than 3 μm distal to the plasma membrane. For the ppMLC-decorated
stress fibers, images were acquired on an iMICAndromeda (FEI) microscope
at with a 40× objective. We analyzed the phosphorylation of Thr18 and/or
Ser19 on the light myosin chain in 90–100 cells from three independent
experiments by using the ‘Unsharp mask’ and the particle analyzer plug-in in
ImageJ software. Objects bigger than 0.5 μm2 were analyzed.
Statistical tests
All data sets were analyzed with R (http://www.R-project.org/). We used an
ANOVA-2 analysis and Tukey’s HSD post-hoc test when necessary. Results
are mean±s.e.m. Significance is indicated with asterisks (*P<0.05,
**P<0.005, ***P<0.0005).
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Supplemental information: 
Supplemental information includes 4 supplemental figures and 8 supplemental 
movies. 
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Fig. S1: Monoubiquitination of ICAP-1  by Smurf1 does not lead to ICAP-1 degradation. 
A. Cycloheximide was added at t=0 to block protein synthesis. The ICAP-1 protein content in 
the total lysates was visualized at the indicated times by Western blotting. The results are 
representative of three independent experiments. B. Quantification of ICAP-1 WT or K158R 
mutant protein levels over a time-course after the inhibition of protein synthesis. The results 
are the mean of three independent experiments. C. CHO lysates overexpressing ICAP-1 
were incubated with immobilized recombinant Smurf1-GST, Smurf2-GST or GST protein as 
a control. Interacting protein was analyzed by Western blotting with the anti-ICAP-1 antibody 
(left panel) and quantified (right panel). The GST protein quantities were controlled using 
Coomassie blue staining. The results are the mean of two independent experiments. D. 
Smurf1-myc and ICAP-1-Flag are co-expressed in CHO cells and coimmunoprecipitated with 
anti-Flag antibodies before blotting against either with anti-Smurf1 or anti-ICAP-1 antibodies. 
E. Elisa assay showing the direct interaction between Smurf1 and ICAP-1 by using purified 
recombinant GST-Smurf1 and purified recombinant ICAP-1-His. 
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Fig. S2: The deletion of Smurf1 leads to focal adhesion disorganization like ICAP-1 
K158R. A. CHO lysates overexpressing the different ICAP-1 constructs were incubated with 
immobilized recombinant 1-integrin-tail-GST, 3-integrin-tail-GST or GST protein as a 
control. The interacting proteins were analyzed by Western blotting with the anti-ICAP-1 
antibody. The GST protein quantities were controlled using Coomassie blue staining. The 
results are representatives of three independent experiments. B. 1 integrin staining of ICAP-
1-null osteoblasts rescued with ICAP-1 WT or the ICAP-1 ubiquitin chimera treated with 
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control or Smurf1 siRNA and spread on FN for 2.5 h. Similar to the cells expressing ICAP-1 
K158R, the cells expressing ICAP-1 WT that were treated with Smurf1 siRNA displayed 
fewer and smaller 1 focal adhesions than the cells treated with control siRNA. C. 
Quantification of the 1 integrin focal adhesion number. D. Distribution of the 1 integrin focal 
adhesion areas. Analyses were performed on 30-40 cells from two independent experiments. 
Error bars indicate SEM. *p< 0.05, **p<0.005, ***p<0.0005. 
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Fig. S3: The deletion of Smurf1 leads to the unresponsiveness of cells to the FN 
density like ICAP-1 K158R. A. Fibronectin density sensing assay in MEF cells. MEF cells 
were spread on increasing concentrations of FN and migration was monitored for 5 h using 
time-lapse microscopy. Cell velocity was determined by individually tracking 150-200 cells 
from three independent experiments. The cells expressing ICAP-1 WT or the ICAP-1 
ubiquitin chimera or cells deficient in ICAP-1 adapted their migratory speed according to the 
FN density, whereas the cells expressing the ICAP-1 K158R mutant maintained the same 
speed regardless of the FN density. B. ICAP-1 WT-expressing osteoblast cells that were 
treated with Smurf1 siRNA were unable to adapt their migratory speed to increasing FN 
density. This defect was rescued by the ICAP-1 ubiquitin chimera. C. 1 integrin-null 
osteoblast cells expressing the 1 integrin mutant that lacks ICAP-1 binding (V787T) were 
not affected by Smurf1 siRNA treatment. D. Rigidity sensing assay in MEF cells. Error bars 
indicate the mean +/- SEM. *p< 0.05, **p<0.005, ***p<0.0005.  
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Fig. S4: Identification of contractile pathway in ICAP-1 Ubi osteoblast cells. A. The level 
of P-myosin is evaluated by western blot in ICAP-1 WT, ICAP-1 deficient and ICAP-1 Ubi 
cells (upper panel). Note the constant level of P-myosin in ICAP-1 Ubi cells whatever the 
substrate rigidity after the quantification of the western blot (bottom panel). B. Osteoblasts 
were spread on FN-coated PAA gels of different rigidities. Cell migration was monitored for 5 
h using time-lapse microscopy. Cell velocity was determined by individually tracking of 200-
300 cells in three independent experiments to test the effect of inhibitors on WT Osteoblasts 
cells and osteoblasts transfected with ICAP-1 Ubi cells on 4kPa gels (Y27632: ROCK 
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inhibitor, 10 M, ML7: MLCK inhibitor, 5 M, SmifH2: mDia inhibitor 2 M).  Note that cells 
expressing ICAP-1 Ubi are insensitive to Y27632.  C. 1 integrin-null cells expressing the 1 
integrin mutant that lacks ICAP-1 binding (V787T) on 4kPa gels responded to Y27632 
treatment in a similar manner to that of the control WT osteoblast cells. 
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Movie S1: Migration of WT osteoblast cells on 1 g/ml FN
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Movie S2: Migration of WT osteoblast cells on 25 g/ml FN 
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Movie S3: Migration of ICAP-1 K158R osteoblast cells on 1 g/ml FN 
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Movie S4: Migration of ICAP-1 K158R osteoblast cells on 25 g/ml FN 
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Movie S5: Migration of WT osteoblast cells on 4 kPa gel coated with 5 g/ml FN 
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Movie S6: Migration of WT osteoblast cells on 50 kPa gel coated with 5 g/ml FN 
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Movie S7: Migration of ICAP-1 Ubi osteoblast cells on 4 kPa gel coated with 5 g/ml FN 
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Movie S8: Migration of ICAP-1 Ubi osteoblast cells on 50 kPa gel coated with 5 g/ml FN 
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